Arrowstreet Capital Limited Partnership Has $88.52 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Arrowstreet Capital Limited Partnership increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 721,200 shares of the biopharmaceutical company’s stock after purchasing an additional 62,544 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Gilead Sciences were worth $88,520,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. Paulson Wealth Management Inc. raised its stake in Gilead Sciences by 1.8% during the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares during the last quarter. Essex Financial Services Inc. raised its stake in Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 71 shares during the last quarter. Alpha Cubed Investments LLC raised its stake in Gilead Sciences by 1.1% during the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares during the last quarter. Personal CFO Solutions LLC raised its stake in Gilead Sciences by 1.7% during the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 76 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC raised its stake in Gilead Sciences by 1.7% during the 4th quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 76 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Down 1.0%

Shares of GILD stock opened at $124.30 on Tuesday. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29. The stock has a market cap of $154.33 billion, a price-to-earnings ratio of 16.93 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The firm has a fifty day moving average of $132.86 and a 200-day moving average of $134.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the prior year, the company posted $1.81 EPS. The business’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Insider Activity

In other news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the transaction, the insider owned 125,779 shares in the company, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the transaction, the chief executive officer owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 62,000 shares of company stock worth $8,182,190. 0.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on GILD. Leerink Partners cut their target price on shares of Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Truist Financial reiterated a “buy” rating and set a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. Barclays began coverage on shares of Gilead Sciences in a research note on Friday, February 20th. They set an “equal weight” rating and a $155.00 target price for the company. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 20th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $156.93.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.